{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:41:14Z","timestamp":1793832074110,"version":"4.6.1"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2021,4,1]]},"DOI":"10.1001\/jamaophthalmol.2020.7085","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T17:41:35Z","timestamp":1614274895000},"page":"441","source":"Crossref","is-referenced-by-count":74,"title":["Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration"],"prefix":"10.1001","volume":"139","author":[{"given":"Ana Bety","family":"Enr\u00edquez","sequence":"first","affiliation":[{"name":"New England Eye Center, Department of Ophthalmology, Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R.","family":"Baumal","sequence":"additional","affiliation":[{"name":"New England Eye Center, Department of Ophthalmology, Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M.","family":"Crane","sequence":"additional","affiliation":[{"name":"Retina-Vitreous Associates of Florida, Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre J.","family":"Witkin","sequence":"additional","affiliation":[{"name":"New England Eye Center, Department of Ophthalmology, Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Lally","sequence":"additional","affiliation":[{"name":"New England Retina Consultants, Springfield, Massachusetts"},{"name":"Department of Surgery, University of Massachusetts Medical School\u2013Baystate, Springfield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle C.","family":"Liang","sequence":"additional","affiliation":[{"name":"New England Eye Center, Department of Ophthalmology, Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Enr\u00edquez","sequence":"additional","affiliation":[{"name":"Harvard University, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Eichenbaum","sequence":"additional","affiliation":[{"name":"Retina-Vitreous Associates of Florida, Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"18","key":"eoi200120r2","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s40265-019-01231-9","article-title":"Brolucizumab: first approval.","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"issue":"10","key":"eoi200120r5","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic anibizumab.","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"issue":"7","key":"eoi200120r6","first-page":"1501","article-title":"Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor A for the treatment of retinal disorders.","volume":"56","author":"Tietz","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"eoi200120r7","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration.","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi200120r8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41433-019-0583-z","article-title":"Brolucizimab\u2014leading an era of structural revolution for long-term VEGF suppression.","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye (Lond)"},{"issue":"10","key":"eoi200120r9","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/s41433-020-0853-9","article-title":"Brolucizumab and immunogenicity.","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye (Lond)"},{"issue":"14","key":"eoi200120r10","first-page":"3025","article-title":"Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration.","author":"Gaudreault","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"eoi200120r11","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study.","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"key":"eoi200120r12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2147\/OPTH","article-title":"Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration.","volume":"13","author":"Yannuzzi","year":"2019","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"eoi200120r13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration.","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"issue":"9","key":"eoi200120r14","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial.","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi200120r16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration.","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"issue":"10","key":"eoi200120r17","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab.","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"eoi200120r18","article-title":"Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration.","volume":"18","author":"Haug","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"eoi200120r19","article-title":"Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations.","volume":"18","author":"Jain","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"4","key":"eoi200120r25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/2474126420930863","article-title":"Occlusive retinal vasculitis following intravitreal brolucizumab.","volume":"4","author":"Witkin","year":"2020","journal-title":"J Vitreoretin Dis"},{"issue":"20","key":"eoi200120r26","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"11","key":"eoi200120r27","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/00006324-197611000-00006","article-title":"New design principles for visual acuity letter charts.","volume":"53","author":"Bailey","year":"1976","journal-title":"Am J Optom Physiol Opt"},{"issue":"6","key":"eoi200120r28","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0002-9394(14)73474-9","article-title":"Relative letter and position difficulty on visual acuity charts from the Early Treatment Diabetic Retinopathy Study.","volume":"116","author":"Ferris","year":"1993","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"eoi200120r29","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3928\/1081-597X-19970701-16","article-title":"Proper method for calculating average visual acuity.","volume":"13","author":"Holladay","year":"1997","journal-title":"J Refract Surg"},{"issue":"2","key":"eoi200120r31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0002-9394(02)01825-1","article-title":"A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol.","volume":"135","author":"Beck","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"eoi200120r32","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jcrs.2004.01.014","article-title":"Visual acuity measurements.","volume":"30","author":"Holladay","year":"2004","journal-title":"J Cataract Refract Surg"},{"issue":"3","key":"eoi200120r33","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1167\/iovs.05-0981","article-title":"Visual acuities \u201chand motion\u201d and \u201ccounting fingers\u201d can be quantified with the Freiburg Visual Acuity Test.","volume":"47","author":"Schulze-Bonsel","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"eoi200120r34","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing Snellen visual acuity measurements.","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina"},{"issue":"10","key":"eoi200120r35","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1167\/iovs.08-1935","article-title":"Intersession repeatability of visual acuity scores in age-related macular degeneration.","volume":"49","author":"Patel","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"eoi200120r36","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/s41433-020-0783-6","article-title":"Using an Excel spreadsheet to convert Snellen visual acuity to logMAR visual acuity.","volume":"34","author":"Tiew","year":"2020","journal-title":"Eye (Lond)"},{"issue":"3","key":"eoi200120r37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop.","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"eoi200120r38","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","article-title":"Standardization of vitreal inflammatory activity in intermediate and posterior uveitis.","volume":"92","author":"Nussenblatt","year":"1985","journal-title":"Ophthalmology"},{"key":"eoi200120r39","article-title":"Brolucizumab\u2014early real-world experience: BREW study.","author":"Sharma","journal-title":"Eye (Lond)"},{"key":"eoi200120r40","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/943409","article-title":"Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy.","volume":"2013","author":"Agrawal","year":"2013","journal-title":"Mediators Inflamm"},{"issue":"3","key":"eoi200120r41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/ICU.0b013e32835f8ec0","article-title":"Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration.","volume":"24","author":"Johnson","year":"2013","journal-title":"Curr Opin Ophthalmol"},{"issue":"5","key":"eoi200120r42","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.ophtha.2012.11.018","article-title":"Aflibercept-related sterile inflammation.","volume":"120","author":"Hahn","year":"2013","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi200120r43","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ajo.2014.06.019","article-title":"Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes.","volume":"158","author":"Goldberg","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"eoi200120r44","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamaophthalmol.2014.5650","article-title":"Postmarketing analysis of aflibercept-related sterile intraocular inflammation.","volume":"133","author":"Hahn","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"eoi200120r45","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.oret.2019.04.006","article-title":"Aflibercept-related sterile intraocular inflammation outcomes.","volume":"3","author":"Greenberg","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"eoi200120r15","author":"Dugel"},{"key":"eoi200120r30","author":"International Council of Ophthalmology"},{"key":"eoi200120r1","unstructured":"Center for Drug Evaluation and Research. Clinical review of BLA 761125. Published 2019. Accessed June 4, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761125Orig1s000MedR.pdf"},{"key":"eoi200120r3","unstructured":"Beovu. Prescribing information. Novartis Pharmaceuticals Corp; 2019. Accessed June 4, 2020. https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/beovu.pdf"},{"key":"eoi200120r4","unstructured":"Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. Assessment report: Beovu. Published 2019. Accessed June 4, 2020. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/beovu-epar-public-assessment-report_en.pdf"},{"key":"eoi200120r20","unstructured":"American Society of Retina Specialists Research and Safety in Therapeutics (ReST) Committee. Adverse events reporting. Accessed June 4, 2020. https:\/\/www.asrs.org\/clinical\/adverse-events-reporting"},{"key":"eoi200120r21","unstructured":"American Society of Retina Specialists Research and Safety in Therapeutics (ReST) Committee. Beovu update. Published 2020. Accessed June 4, 2020. https:\/\/www.asrs.org\/clinical\/clinical-updates\/1968\/Beovu-Update"},{"key":"eoi200120r22","unstructured":"American Society of Retina Specialists. Novartis-appointed safety review committee reports initial brolucizumab findings. Published June 4, 2020. Accessed July 19, 2020. http:\/\/www.brolucizumab.info\/sites\/brolucizumab_info\/files\/2020-07\/ASRS_SRC_report.pdf"},{"key":"eoi200120r23","unstructured":"Novartis Pharmaceuticals Corporation. Novartis provides update on use and safety of Beovu (brolucizumab). Published July 17, 2020. Accessed July 19, 2020. https:\/\/www.brolucizumab.info\/#safety-event-information"},{"key":"eoi200120r24","doi-asserted-by":"crossref","unstructured":"Witkin? AJ, Hahn? P, Murray? TG. Occlusive retinal vasculitis following intravitreal brolucizumab: an ASRS Research and Safety in Therapeutics (ReST) Committee report. American Society of Retina Specialists. Published 2020. Accessed June 4, 2020. https:\/\/www.asrs.org\/publications\/retina-times\/details\/3937\/occlusive-retinal-vasculitis-following-intravitreal-brolucizumab-an-asrs-research-and-safety-in-ther","DOI":"10.1177\/2474126420930863"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2776731\/jamaophthalmology_enrquez_2021_oi_200120_1618442128.68621.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T12:31:43Z","timestamp":1619094703000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2776731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.7085","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}